Liraglutide: A once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus

Expert Opinion on Investigational Drugs

Volumn 16, Issue 2, 2007, Pages 231-237

  Vilsbøll, Tina ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

GLP 1; Glycaemic control; Liraglutide; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; PLACEBO; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ADD ON THERAPY; ARTICLE; BODY WEIGHT; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE MODEL; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PHARMACODYNAMICS; SINGLE DRUG DOSE; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; GLUCAGON-LIKE PEPTIDE 1; HUMANS;

EID: 33846799072     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.2.231     Document Type: Article

References (67)

1. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352(9131):837-853.
2. VILSBOLL T, HOLST JJ: Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia (2004) 47(3):357-366.
3. NAUCK MA, HOMBERGER E, SIEGEL EG et al.: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. (1986) 63(2):492-498.
4. NAUCK M, STOCKMANN F, EBERT R, CREUTZFELDT W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia (1986) 29(1):46-52.
5. VILSBOLL T, KRARUP T, DEACON CF, MADSBAD S, HOLST JJ: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in Type 2 diabetic patients. Diabetes (2001) 50(3):609-613.
6. VILSBOLL T, KRARUP T, MADSBAD S, HOLST JJ: Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia (2002) 45(8):1111-1119.
7. VILSBOLL T, KNOP FK, KRARUP T et al.: The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J. Clin. Endocrinol. Metab. (2003) 88(10):4897-903.
8. KJEMS LL, HOLST JJ, VOLUND A, MADSBAD S: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in Type 2 and nondiabetic subjects. Diabetes (2003) 52(2):380-386.
9. HØJBERG P, VILSBOLL T, ZANDER M et al.: Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 secretion but enhances β-cell responsivenes during a meal in patients with Type 2 diabetes. Diabetes (2006):A365.
10. DRUCKER DJ, NAUCK MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet (2006) 368(9548):1696-1705.
11. ORSKOV C, WETTERGREN A, HOLST JJ: Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand. J. Gastroenterol. (1996) 31(7):665-670.
12. LAYER P, HOLST JJ, GRANDT D, GOEBELL H: Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig. Dis. Sci. (1995) 40(5):1074-1082.
13. NAUCK MA, HEIMESAAT MM, ORSKOV C, HOLST JJ, EBERT R, CREUTZFELDT W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not ofsynthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. (1993) 91(1):301-307.
14. ORSKOV C, HOLST JJ, NIELSEN OV: Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology (1988) 123(4):2009-2013.
15. FLINT A, RABEN A, ASTRUP A, HOLST JJ: Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. (1998) 101(3):515-520.
16. WILLMS B, WERNER J, HOLST JJ, ORSKOV C, CREUTZFELDT W, NAUCK MA: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in Type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. (1996) 81(1):327-332.
17. NAUCK MA, NIEDEREICHHOLZ U, ETTLER R et al.: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. (1997) 273(5 Part 1):E981-E988.
18. NIKOLAIDIS LA, MANKAD S, SOKOS GG et al.: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation (2004) 109(8):962-965.
19. GOKE R, LARSEN PJ, MIKKELSEN JD, SHEIKH SP: Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. (1995) 7(11):2294-300.
20. ORSKOV C, POULSEN SS, MOLLER M, HOLST JJ: Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes (1996) 45(6):832-835.
21. NAGELL CF, WETTERGREN A, ORSKOV C, HOLST JJ: Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scand. J. Gastroenterol. (2006) 41(6):667-672.
22. MURPHY KG, DHILLO WS, BLOOM SR: Gut peptides in the regulation of food intake and energy homeostasis. Endocr. Rev. (2006) (In Press).
23. EGAN JM, BULOTTA A, HUI H, PERFETTI R: GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet β cells. Diabetes Metab. Res. Rev. (2003) 19(2):115-123.
24. BONNER-WEIR S, WEIR GC: New sources of pancreatic β-cells. Nat. Biotechnol. (2005) 23(7):857-861.
25. STOFFERS DA, KIEFFER TJ, HUSSAIN MA et al.: Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes (2000) 49(5):741-748.
26. ZHOU J, WANG X, PINEYRO MA, EGAN JM: Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells, Diabetes (1999) 48(12):2358-2366.
27. HUI H, NOURPARVAR A, ZHAO X, PERFETTI R: Glucagon-like pepticle-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology (2003) 144(4):1444-1455.
28. BRUBAKER PL, DRUCKER DJ: Minireview: glucagon-like peptides regulate cell proliferation arid apoptosis in the pancreas, gut, and central nervous system. Endocrinology (2004) 145(6):2653-2659.
29. BUTLER AE, JANSON J, BONNER-WEIR S, RITZEL R, RIZZA RA, BUTLER PC: β-cell deficit and increased β-cell apoptosis in humans with Type 2 diabetes. Diabetes (2003) 52(1):102-110.
30. NAUCK MA, WEBER I, BACH I et al.: Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2 diabetic patients. Diabet. Med. (1998) 15(11):937-945.
31. ZANDER M, MADSBAD S, MADSEN JL, HOLST JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in Type 2 diabetes: a parallel-group study. Lancet (2002) 359(9309):824-830.
32. 2-terminus in Type II diabetic patients and in healthy subjects. Diabetes (1995) 44(9):1126-1131.
33. DEACON CF, NAUCK MA, MEIER J, HUCKING K, HOLST JJ: Degradation of enclogenous and exogenous gastric inhibitory polypeptide in healthy and in Type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. (2000) 85(10):3575-3581.
34. VILSBOLL T, AGERSO H, KRARUP T, HOLST JJ: Similar elimination rates of glucagon-like peptide-1 in obese Type 2 diabetic patients arid healthy subjects. J. Clin. Endocrinol. Metab. (2003) 88(1):220-224.
35. AGERSO H, JENSEN LB, ELBROND B, ROLAN P, ZDRAVKOVIC M: The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia (2002) 45(2):195-202.
36. DEGN KB, JUHL CB, STURIS J et al.: One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with Type 2 diabetes. Diabetes (2004) 53(5):1187-1194.
37. DAMHOLT B, GOLOR G, WIERICH W, PEDERSEN P, EKBLOM M, ZDRAVKOVIC M: An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J. Clin. Pharmacol. (2006) 46(6):635-641.
38. ROLIN B, LARSEN MO, GOTFREDSEN CF et al.: The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am. J. Physiol. Endocrinol. Metab. (2002) 283(4):E745-E752.
39. STURIS J, GOTFR-EDSEN CF, ROMER J et al.: GLP-1 derivative liraglutide in rats with β-cell deficiencies: influence of metabolic state on β-cell mass dynamics. Br. J. Pharmacol. (2003) 140(1):123-132.
40. MADSBAD S, SCHMITZ O, RANSTAM J, JAKOBSEN G, MATTHEWS DR: Improved glycemic control with no weight increase in patients with Type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care (2004) 27(6):1335-1342.
41. VILSBOLL T, ZDRAVKOVIC M, LE-THI T et al.: Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with Type 2 diabetes. Diabetes (2006):A115.
42. NAUCK MA, EL-OUAGHLIDI A, HOMPESCH M, JAKOBSEN J, ELBROEND B: No impairment of hypoglycemia counterregulation via glucagon with the long-acting GLP-1 derivative, NN2211, in subjects with Type 2 diabetes. Diabetologia (2003):A285.
43. BOCK T, PAKKENBERG B, BUSCHARD K: The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS (2003) 111(12):1117-1124.
44. LARSEN PJ, FLEDELIUS C, KNUDSEN LB, TANG-CHRISTENSEN M: Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes (2001) 50(11):2530-2539.
45. RIBEL U, LARSEN MO, ROLIN B et al.: NN2211: a long-acring glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur. J. Pharmacol. (2002) 451(2):217-225.
46. PIPER K, DIJKSTRA I, DUNLEAVEY L, HANLEY NA: The long-acting GLP-1 analog, liraglutide, increases X cell numbers during early human development. Diabetologia (2005):A151.
47. HUI H, WANG C, XU J, HUI Z, PERFETTI R: Liraglutide inhibits cell death in human isolated islets by regulating the expression of apoptosis-related genes. Diabetes (2006):A1993.
48. CHANG AM, JAKOBSEN G, STURIS J, et al.: The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in Type 2 diabetic patients after a single dose. Diabetes (2003) 52(7):1786-1791.
49. FEINGLOS MN, SAAD MF, PI-SUNYER FX, AN B, SANTIAGO O: Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet. Med. (2005) 22(8):1016-1023.
50. HARDER H, NIELSEN L, TU DT, ASTRUP A: The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with Type 2 diabetes. Diabetes Care (2004) 27(8):1915-1921.
51. AMERICAN DIABETES ASSOCIATION: Standards of medical care in diabetes. Diabetes Care (2005) 28(Suppl. 1):S4-S36.
52. MADSBAD S, BROCK B, PERRILD H et al.: Fourteen weeks of liraglutide therapy in subjects with Type 2 diabetes significantly improves first phase insulin secretion and maximal β-cell secretory capacity. Diabetologia (2006):A0004.
53. VILSBOLL T, ZDRAVKOVIC M, LE-THI T et al.: Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with Type 2 diabetes: 14 weeks monotherapy study. Diabetes (2006):A2007.
54. NAUCK MA, HOMPESCH M, FILIPCZAK R, LE TD, ZDRAVKOVIC M, GUMPRECHT J: Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes (2006) 114(8):417-423.
55. RITZEL R, ORSKOV C, HOLST JJ, NAUCK MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia (1995) 38(6):720-725.
56. VILSBOLL T, KRARUP T, MADSBAD S, HOLST JJ: No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet. Med. (2001) 18(2):144-149.
57. NAUCK MA, HOLST JJ, WILLMS B: Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm. Metab. Res. (1997) 29(9):411-416.
58. NAUCK M: Insulin secretagogues. Topic Endocrinol. (1999) 11:6-10.
59. FEINGLOS M, DAILEY G, CEFALU W et al.: Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res. Clin. Pract. (2005) 68(2):167-175.
60. HEINE RJ, VAN GAAL LF, JOHNS D, MIHM MJ, WIDEL MH, BRODOWS RG: Exenatide versus insulin glargine in patients with suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med. (2005) 143(8):559-569.
61. WARD WK, BEARD JC, PORTE D Jr: Clinical aspects of islet B-cell function in non-insulin-dependent diabetes mellitus. Diabetes Metab. Rev. (1986) 2(3-4):297-313.
62. GERICH JE: Abnormal glucagon secretion in Type 2 (nioninsulindependent) diabetes mellitus: cause or consequence. In: Diabetes mellitas., pathophysiology and therapy. Creurzfeldt W, Lefebvre P (Eds), Springer Verlag, Berlin, Germnay (1989):127-133.
63. SCHWARTZ JG, GREEN GM, GUAN D, McMAHAN CA, PHILLIPS WT. Rapid gastric emptying of a solid pancake meal in Type II diabetic patients. Diabetes Care (1996) 19(5):468-471.
64. KOLTERMAN OG, KIM DD, SHEN L et al.: Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with Type 2 diabetes mellitus. Am. J. Health Syst. Pharm. (2005) 62(2):173-181.
65. ASCHNER P, KIPNES M, LUNCEFORD J et al.: Sitagliptin monotherapy improved glycaemic control in patients with Type 2 diabetes. Diaberologia (2006):0005 (Abstract).
66. DEACON CF, HOLST JJ: Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of Type 2 diabetes. Int. J. Biochem. Cell Biol. (2006) 38(5-6):831-844.
67. PRATLEY RE, JAUFFRET-KAMEL S, GALBREATH E, HOLMES D: Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with Type 2 diabetes. Horm. Metab. Res. (2006) 38(6):423-428.